Results 51 to 60 of about 2,458 (200)

Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS/MS Method

Frontiers in Pharmacology, 2022
Umbralisib is a dual inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ) and casein kinase 1 epsilon (CK1ε) for treating marginal zone lymphoma (MZL) and follicular lymphoma (FL).
Qinghua Weng, Xia Lan, Yingjie Wang, Chen Fan, Ren-ai Xu, Pengzhao Zhang   +5 more
doaj   +1 more source

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells [PDF]

, 2017
Activation-induced cytidine deaminase (AID) is a B-cell specific enzyme that targets immunoglobulin (Ig) genes to initiate class switch recombination (CSR) and somatic hypermutation (SHM)(1).
Alt, Frederick W., Ambrogio, Chiara, Blasco, Rafael B., Brown, Jennifer R., Catherine J., Wu, Cheong, Taek Chin, Chiarle, Roberto, Compagno, Mara, Gostissa, Monica, Karaca, Elif, Kasar, Siddha N., Langellotto, Fernanda, Meng, Fei Long, Pighi, Chiara, Poggio, Teresa, Sun, Jing, Voena, Claudia, Wang, Qi, Wiestner, Adrian, Yeap, Leng Siew   +19 more
core   +2 more sources

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

Leukemia Research Reports, 2015
PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms ...
Matthew D. Blunt, Andrew J. Steele
doaj   +1 more source

Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study

Frontiers in Pharmacology, 2021
Alpelisib, an oral selective and small-molecule phosphoinositide 3-kinase inhibitor, was lately approved in the United States to treat breast cancer. A sensitive method to quantify alpelisib levels in rat plasma on the basis of ultra-performance liquid ...
Qiong Wang, Xia Lan, Zhuofei Zhao, Xiaohang Su, Yuji Zhang, Xiao-Yang Zhou, Ren-Ai Xu   +6 more
doaj   +1 more source

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma [PDF]

, 2019
PURPOSE Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies.
Abou-Nassar, Karem-Etienne, Ardeshna, Kirit, Assouline, Sarit, Crump, Michael, de Vos, Sven, Flinn, Ian, Jacobsen, Eric, Kelly, Virginia, Le, NgocDiep, Lunin, Scott, Lustgarten, Stephanie, Mayer, Jiri, Merli, Michele, Miller, Carole, Nagy, Zoltan, Pettitt, Andrew, Shi, Weiliang, Steelman, Lori, Tetreault, Scott, Tournilhac, Olivier, Wagner-Johnston, Nina, Weaver, David, Zinzani, Pier Luigi   +22 more
core   +4 more sources

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study [PDF]

, 2023
Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit with monotherapy in a phase 2 study in relapsed or refractory (R/R) follicular lymphoma (FL).
Boccia R., Coleman M., Cordoba R., Duras J., Hamadani M., Hutchings M., Langmuir P., Liu H., Oreiro M. B., Sancho J. -M., Stouffs M., Williams V., Zinzani P. L.   +12 more
core   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9.

PLoS Computational Biology, 2022
Cytochrome P450 2C9 (CYP2C9) is a major drug-metabolizing enzyme that represents 20% of the hepatic CYPs and is responsible for the metabolism of 15% of drugs.
Elodie Goldwaser, Catherine Laurent, Nathalie Lagarde, Sylvie Fabrega, Laure Nay, Bruno O Villoutreix, Christian Jelsch, Arnaud B Nicot, Marie-Anne Loriot, Maria A Miteva   +9 more
doaj   +1 more source

Duvelisib Approved for Leukemia, Lymphoma [PDF]

Cancer Discovery, 2018
Abstract The FDA approved duvelisib, a PI3Kδ/PI3Kγ inhibitor, for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least two prior therapies. The agency also granted the drug an accelerated approval for patients with relapsed/refractory follicular lymphoma following at least ...
openaire   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source